Subscribe
Marlon Trottmann / Shutterstock.com
15 August 2024NewsAmericasMuireann Bolger

Pfizer loses $107.5m AstraZeneca verdict after voiding cancer patents

AstraZeneca successfully argued that “no reasonable jury” could find it had infringed the patents-in-suit claiming lung cancer patents | Reprieve comes after misconduct allegations against a Pfizer unit fell flat earlier this month.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Pfizer fends off misconduct claims to keep $107.5m award
8 August 2024   A Delaware jury found AstraZeneca liable for induced infringement of a cancer treatment in May | Pharma company levelled allegations of "unclean hands" and "patent misuse" at Pfizer unit.
Americas
Pfizer sues Chinese pharma firm over prostate cancer drug
6 August 2024   Big pharma subsidiary and Japanese collaborator allege infringement of blockbuster drug product | $1.2 billion treatment developed by University of California.


Editor's picks

Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

Editor's picks

Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024
Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Europe
Labour govt appoints new Minister with IP oversight
9 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024
Americas
Amarin wins appeal to advance ‘skinny label’ suit over Hikma generic
27 June 2024

More on this story

Americas
Pfizer fends off misconduct claims to keep $107.5m award
8 August 2024   A Delaware jury found AstraZeneca liable for induced infringement of a cancer treatment in May | Pharma company levelled allegations of "unclean hands" and "patent misuse" at Pfizer unit.
Americas
Pfizer sues Chinese pharma firm over prostate cancer drug
6 August 2024   Big pharma subsidiary and Japanese collaborator allege infringement of blockbuster drug product | $1.2 billion treatment developed by University of California.

More on this story

Americas
Pfizer fends off misconduct claims to keep $107.5m award
8 August 2024   A Delaware jury found AstraZeneca liable for induced infringement of a cancer treatment in May | Pharma company levelled allegations of "unclean hands" and "patent misuse" at Pfizer unit.
Americas
Pfizer sues Chinese pharma firm over prostate cancer drug
6 August 2024   Big pharma subsidiary and Japanese collaborator allege infringement of blockbuster drug product | $1.2 billion treatment developed by University of California.

More features

HLK adds CRISPR specialist as partner
Novo Nordisk files fresh lawsuits to intercept Wegovy generics
UPC delivers first 'imminent infringement' decision in biosimilar dispute
AstraZeneca unit draws line under Samsung dispute
Brown Rudnick expands with new partner duo
UPC: First decisions on merits are ‘testimony to judges’ tight case management’
Morgan Lewis adds two partners to London office
UK firm prevails in ‘exceptionally slow’ UPC test case